Acquired

Synthorx Stock

Biotechnology

Sign up today and learn more about Synthorx Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

Founded

2014

Notable Investors

Correlation Ventures

Headquarters

La Jolla CA, US

Total Funding

$79.0M

About Synthorx Stock

Synthorx is a biotechnology company using ground-breaking synthetic biology starting with our novel DNA base pair to discover and develop new protein therapeutics. The company uses new building blocks to create proteins that impart specificity not possible with native proteins. The result is treatments with improved efficacy, better safety, and better convenience for patients. Utilizing proprietary engineered organisms we have the ability to manufacture these improved proteins with high fidelity and the required yield for drug discovery and development. This unique platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies.

Investors

Funding History

April 2014$6.0M
July 2016$10.0M
April 2018$63.0M

Management

Chief Scientific Officer

Marcos Milla

President and CEO

Laura Shawver

Founder and Director

Floyd E. Romesberg

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo